Where are they concentrated in India?
The Atlas records these city concentrations in India, each with
three or more organizations holding a recorded site in the city.
An organization with sites in two of these cities is counted
in both, so these figures add up to more than the number of
organizations they cover.
- 11 Bengaluru
- 6 Gurugram
- 5 Mumbai
- 4 Hyderabad
A further 13 organizations hold
no recorded site in any city listed above, whether because the site
is in a smaller city in India or because no site is on record.
Counted for the country, not shown as a concentration.
How is longevity medicine regulated in India?
India regulates in two registers at once. Non-transplant stem cell therapy is investigational under national guidelines that carry no statutory penalty, while a separate rule makes a stem-cell-derived product a new drug needing central approval. No category is specific to longevity.
- No dedicated longevity category exists. Clinical establishments register under a national act with uneven state adoption.
- State authorities; Central Drugs Standard Control Organisation, Clinical Establishments Act 2010, effective 2010.
- The National Guidelines for Stem Cell Research state that no stem cell therapy is an approved standard of care other than blood stem cell transplantation and that all other use is investigational. These are guidelines, not a statute, and carry no standalone penalty.
- Indian Council of Medical Research; Department of Biotechnology, National Guidelines for Stem Cell Research 2017, issued 2017.
Primary source
.
- A separate rule classifies a stem-cell-derived product as a new drug requiring central approval, which is the binding statutory hook.
- Central Drugs Standard Control Organisation, New Drugs and Clinical Trials Rules 2019, effective March 19, 2019.
Primary source
.
- Laboratory standards fall under the Clinical Establishments Act, and advertising claims for treatments fall under a separate act.
- State authorities, Drugs and Magic Remedies (Objectionable Advertisements) Act 1954, effective 1954.
Medium-high confidence. The gap between the 2017 guidelines and clinical practice, and the limits of enforcement capacity, are characterized from a peer-reviewed analysis rather than a primary instrument.
For how India compares with other markets, see
Longevity Clinic Regulation, Market by Market
.